Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erbitux plus irinotecan/5-fluorouracil/leucovorin/oxaliplatin as neoadjuvant chemotherapy for colorectal liver metastases
2005-006205-28Phase 2Completed
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Sep 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal cancer (CRC), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Resection rate of liver metastases. Started Sep 2007; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2005-006205-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006205-28.